{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06465186",
            "orgStudyIdInfo": {
                "id": "6024-017"
            },
            "secondaryIdInfos": [
                {
                    "id": "2024-510923-20",
                    "type": "OTHER",
                    "domain": "EU CT"
                },
                {
                    "id": "MK-6024-017",
                    "type": "OTHER",
                    "domain": "Merck"
                },
                {
                    "id": "jRCT2031240217",
                    "type": "REGISTRY",
                    "domain": "jRCT"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)",
            "officialTitle": "Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis",
            "therapeuticArea": [
                "Other",
                "Gastroenterology"
            ],
            "study": "a-clinical-study-of-efinopegdutide-in-people-with-compensated-cirrhosis-due-to-steatohepatitis-mk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-05-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-13",
            "studyFirstSubmitQcDate": "2024-06-13",
            "studyFirstPostDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn:\n\n* If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver\n* About the safety of efinopegdutide and how well people tolerate it"
        },
        "conditionsModule": {
            "conditions": [
                "Non-alcoholic Fatty Liver Disease",
                "Nonalcoholic Steatohepatitis",
                "NAFLD",
                "Metabolic Dysfunction-associated Steatotic Liver Disease",
                "Metabolic Dysfunction-associated Steatohepatitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Efinopegdutide",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will start efinopegdutide once a week at the lowest dose level. Then, the dose level will go up every month for three months until they are getting the highest dose level. Efinopegdutide is given as an injection under the skin (subcutaneous injection) for 28 weeks.",
                    "interventionNames": [
                        "Combination Product: Efinopegdutide"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive placebo once a week. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.\n\nPlacebo is given as an injection under the skin (subcutaneous injection) for 28 weeks.",
                    "interventionNames": [
                        "Combination Product: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Efinopegdutide",
                    "description": "Efinopegdutide is given as a subcutaneous injection using a single-use prefilled syringe, once per week for 28 weeks",
                    "armGroupLabels": [
                        "Efinopegdutide"
                    ],
                    "otherNames": [
                        "MK-6024"
                    ]
                },
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Placebo",
                    "description": "Placebo is given as a subcutaneous injection using a single-use prefilled syringe once per week for 28 weeks.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from Baseline in Liver Fat Content (LFC) at Week 28",
                    "description": "Researchers will measure the change in the amount of fat in the liver using magnetic resonance imaging (MRI) after about 7 months of treatment.\n\nThe change in MRI-Estimated proton density fat fraction (PDFF) will be measured from baseline to 28 weeks.",
                    "timeFrame": "Baseline and 28 weeks"
                },
                {
                    "measure": "Percentage of Participants Who Experienced an Adverse Event (AE)",
                    "description": "An AE is a health problem that happens or worsens during the study",
                    "timeFrame": "Up to approximately 36 weeks"
                },
                {
                    "measure": "Percentage of Participants Discontinuing Study Medication Due to an AE",
                    "description": "An AE is a health problem that happens or worsens during a study. The percentage of participants who stop study treatment due to an AE will be reported.",
                    "timeFrame": "Up to approximately 28 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from Baseline in Iron-corrected T1 (cT1) at Week 28",
                    "description": "Researchers will measure the change in liver inflammation and scarring (fibrosis) after about 7 months of treatment.\n\nMRI measurement of cT1 mapping will be used to indicate the amount of liver inflammation and fibrosis. The change in cT1 mapping from baseline to 28 weeks will be presented.",
                    "timeFrame": "Baseline and up to 28 Weeks"
                },
                {
                    "measure": "Change from Baseline in Enhanced Liver Fibrosis (ELF)",
                    "description": "Researchers will measure the change in liver scarring using biomarkers. Biomarkers are substances measured in blood that show normal or abnormal activity taking place in the liver.\n\nELF is calculated using 3 markers of hepatic extracellular matrix turnover to generate a unitless numerical score. The change from baseline in ELF up to 28 weeks will be reported.",
                    "timeFrame": "Baseline and up to 28 weeks"
                },
                {
                    "measure": "Change from Baseline in Propeptide of Type III Collagen (Pro-C3) at Week 28",
                    "description": "Researchers will measure the change in liver scarring using biomarkers.\n\nPro-C3 is measured in serum; Increasing levels indicate worsening of fibrosis activity. The change in Pro-C3 from baseline to 28 weeks will be reported.",
                    "timeFrame": "Baseline and up to 28 weeks"
                },
                {
                    "measure": "Change from Baseline in Fibrosis-4 index (FIB-4) at Week 28",
                    "description": "Researchers will measure the change in liver scarring using biomarkers.\n\nFIB-4 index is calculated using the participant's age and 3 serum markers (alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], and platelet count). The change from baseline in FIB-4 after 28 weeks will be reported.",
                    "timeFrame": "Baseline and up to 28 weeks"
                },
                {
                    "measure": "Change from Baseline in Liver Stiffness Measurement (LSM) Assessed by Vibration-controlled Transient Elastography (VCTE) at week 28",
                    "description": "Researchers will measure the change in liver scarring using ultrasound.\n\nLSM is measured using VCTE. The change from baseline in LSM after 28 weeks will be reported.",
                    "timeFrame": "Baseline and up to 28 weeks"
                },
                {
                    "measure": "Percent Change from Baseline in Body Weight at Week 28",
                    "description": "Body weight will be measured using a standardized, digital scale. The percent change from baseline in body weight after 28 weeks will be reported",
                    "timeFrame": "Baseline and up to approximately 28 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH)\n* Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has history of a liver disease other than MASH, for example, Hepatitis B or C, drug-induced liver disease, or autoimmune liver disease\n* Has history of type 1 diabetes\n* Had a bariatric surgical procedure less than 5 years before entry into the study\n* History of pancreatitis\n* Major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Synergy Healthcare ( Site 0118)",
                    "status": "RECRUITING",
                    "city": "Bradenton",
                    "state": "Florida",
                    "zip": "34208",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "941-780-1415"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.49893,
                        "lon": -82.57482
                    }
                },
                {
                    "facility": "Floridian Clinical Research, LLC ( Site 0109)",
                    "status": "RECRUITING",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33016-1518",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "954-439-0531"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Klinical Investigations Group-Clinical Research ( Site 0601)",
                    "status": "RECRUITING",
                    "city": "San Juan",
                    "zip": "00909",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "7879197865"
                        }
                    ],
                    "geoPoint": {
                        "lat": 18.46633,
                        "lon": -66.10572
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "https://www.merckclinicaltrials.com"
                },
                {
                    "label": "Plain Language Summary",
                    "url": "https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=6024-017&&kw=6024-017"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000005234",
                    "term": "Fatty Liver"
                },
                {
                    "id": "D000065626",
                    "term": "Non-alcoholic Fatty Liver Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8375",
                    "name": "Fatty Liver",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30540",
                    "name": "Non-alcoholic Fatty Liver Disease",
                    "asFound": "Non-alcoholic Fatty Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "asFound": "Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5868",
                    "name": "Visceral Steatosis",
                    "asFound": "Steatohepatitis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}